The blood vessel system is the first organ to arise during development. Understanding of blood and vascular development will improve the development of treatments for cancer, heart disease, and diabetes. Blood vessel development occurs via the common origin of hemangioblasts, the endothelial and primitive blood cells precursor from mesoderm.
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1) The hemangioblast can arise from the presumptive gastrula-stage mesoderm in Xenopus.
2) However, developmental mechanisms that the endothelial and primitive blood cells are arisen from hemangioblast are not clearly identified.
Activin, a member of the transforming growth factor beta family, is a crucial morphogen during development and differentiation in various vertebrates. 3, 4) Activin converts animal cap cells, pluripotent cells in the ectodermal region of amphibian blastula embryo, into mesoderm and endoderm in a dose-dependent manner. Activin at low concentrations induces ventral mesoderm, such as blood cells, coelomic epithelium and mesenchyme, 5, 6) while at high concentrations, it induces notochord, the most dorsal mesoderm, and endoderm. 7) In fact, beating heart can be induced from animal caps treated with 100 ng/ml activin. 8) Aggregates prepared from Xenopus blastula animal cap cells treated with 25 ng/ml or 100 ng/ml activin and then transplanted into normal embryo developed into maxillofacial tissue or beating heart accompanying surrounding tissue formation, respectively. 3, 9) This study treated aggregates of animal cap cells with a low concentration (0.4 ng/ml) of activin and showed that large numbers of red blood cells and vascular endothelial cells could be formed by transplantation of the aggregates into a host embryo. We also looked for novel vascular-related genes by analysing the gene expression profiles of the activin-treated and untreated aggregates.
MATERIALS AND METHODS

Generation of Aggregates
Fertilization, embryo culture, and staging were performed as described previously. 10) Enhanced green fluorescence protein (EGFP) mRNA was injected into the animal pole of 2-cell embryos. Presumptive ectodermal sheets (0.5 mmϫ0.5 mm) cut from the late blastulae (stage 9) were dissociated in Ca 2ϩ -and Mg 2ϩ -free (CMF) Steinberg's solution containing 0.1% fatty acid-free bovine serum albumin (Sigma). The dissociated cells were treated with 0.4 ng/ml activin in CMF-Steinberg's solution for 1 h, and were then aggregated and cultured in Steinberg's solution for 3 d at 20°C.
Transplantation One quarter of an aggregate cultured for 24 h was transplanted into the lateral region of stage-23 embryos. The transplanted embryos were cultured in Steinberg's solution at 20°C.
Probes Sequences for X-msr (583 bp) and globin T3 (204 bp) were amplified from cDNA prepared from stage 18-42 embryos by PCR, and cloned into the pGEM-eazy vector (Invitrogen). Primer sequences were described previously. 10) For probe preparation, the cRNAs incorporating DIG-labeled CTP were prepared from these cDNAs by in vitro transcription according to the manufacturer's instructions (Roche).
In Situ Hybridization Sectioned in situ hybridization was carried out using the discovery system (Ventana Medical Systems, Inc.), as described previously.
10)
Immunohistochemistry The aggregates were fixed in 10% formamide for 1 d, embedded in paraffin, and the sectioned at 6 mm. After depareffinization, the sections were immunostained with an anti-EGFP antibody, and visualized with peroxidase-conjugated Simple Stain MAX PO goat anti-rabbit IgG (Nichirei) and 3-amino-9-ethylcarbazol (AEC, Nichirei).
Microarray Analysis Total RNA was extracted from two aggregates after 24 h in culture using Isogen (Nippongene, Japan). Extracted RNA was labelled with Cy-dye using a Low RNA input linear amplification kit following the manufacturer's instructions (Agilent Technology). In brief, dsDNA was synthesized from extracted RNA with oligo dT primer containing the T7 promoter, then cRNA was synthesized using T7 polymerase with either Cy3-dCTP or Cy5-dCTP (Amersham). Labeled cRNAs were hybridized to the DNA microarray, which was then washed in 6ϫSSC, 0.05% TritonX-102 at 20°C, and then in 0.1ϫSSC, 0.005% TritonX-102 at 4°C. Data analysis was performed using the Rosetta Luminator system (Rosetta Biosoftware). The level of significance was pϹ0.01 (two-sided). The Xenopus custom oligomicroarray, with 60-mer oligo DNA, was supplied by Agilent Technology. Probes for each spot were designed from about 24,000 clusters of NCBI UniGene Build 59 and the gene we sequenced, with a final selection of 21,227 probes.
RESULTS
Transplantation of the Xenopus Embryo Aggregates
Cells dissociated from Xenopus animal caps (stage 9) were treated with 0.4 ng/ml activin and then aggregated, named activin-treated aggregates. One day later, these were transplanted into the ventral region of stage-23 embryos (Fig.  1A) . A protuberance with red coloration was detected in the host embryo transplanted with the activin-treated aggregate after 3 d (Fig. 1B) . No morphological changes were observed in the host embryos harboring the untreated aggregates (data not shown). In situ hybridization of sections using globin T3 and X-msr probes confirmed the presence of blood and vas- cular endothelial cells, respectively, in the transplanted aggregate. The globin T3 mRNA was abundantly expressed in the transplanted aggregate (Fig. 1C) , surrounded by X-msr positive cells (Fig. 1D) .
Localization of Aggregate in Host Embryo
The derivation of the tissue in the protuberance of the host embryo was established by using animal caps from fertilized eggs injected with enhanced green fluorescent protein (EGFP) as a tracer. Fluorescent microscope imaging revealed EGFP signal in the ventral region of embryos transplanted with untreated aggregates (Fig. 2A) . In embryos hosting the activintreated aggregates, EGFP signal was apparent only in the protuberance on the ventral side (Fig. 2B) . After growing the embryos until red blood cells were generated in the transplants, the location of EGFP signal was the same as in early embryos (Figs. 2C, D) . These results demonstrated that the tissue in the protuberance of embryos harboring activintreated aggregates was derived from animal cap cells and not from the host tissue. The localization of the cells treated with or without activin in the transplant was further investigated by immunostaining sections of host embryo with an anti-EGFP antibody. This antibody staining localized the EGFP expression to the epidermis in embryos harboring the untreated aggregates (Fig. 2E) , while blood and vascular endothelial cells stained positively in embryos hosting the activin-treated aggregates (Fig. 2F) . These results demonstrated that activin treatment of animal caps induced blood and vascular development.
The aggregates were cultured in Steinberg's solution for 5 d in vitro (corresponds to stage-42 embryo development); however, red blood cells were not formed after this time (Figs. 2G, H) . This suggested that an unknown factor secreted from the host embryo stimulated cell differentiation of activin-treated cells in the transplanted aggregates into blood cells or their surrounding vascular endothelial cells.
Microarray Analysis Based on the results with the transplanted aggregates, we analysed gene expression profiles in the aggregates to identify genes induced in the activin-treated cells. We chose receptor genes as the starting point of cellular signal transduction, and performed microarray analysis using a 60-mer oligo DNA array and spotting of 21,227 clones. Comparison of gene expression revealed that 858 clones were expressed at levels at least 2-fold greater in activin-treated aggregates than in the untreated cells. Of these, 356 had already been described in Xenopus, 296 were homologues, and 186 were expressed sequence tags (ESTs) in the NCBI database. Microarray analysis indicated that 19 receptor genes including five homologous genes were induced in the animal cap cells by activin treatment (Table 1) 6) In addition, we showed recently that activintreated aggregates did not induce the formation of blood cells. 10) In our present study, abundant red blood cells were apparent in the transplanted aggregate, implicating a hostsecreted co-factor in the vascular system differentiation.
Layer of mural cells such as vascular smooth muscle cells and pericytes that are present in large vessels were not observed in the transplanted aggregates, suggesting that the tissues induced in this study were peripheral vasculature. Yamashita et al. reported that Flk1-positive cells derived from embryonic stem cells could differentiate into both endothelial and mural cells. 11) However, endothelial and mural cell differentiation is promoted by VEGF and PDGF-BB, respectively, indicating distinct cell-specific differentiation mecha- Probable G protein_coupled receptor GPR4-human nisms. 11) Our microarray data revealed induction of the PDGFR gene in activin-treated aggregates, and PDGFR is expressed in mural cells with roles in cell proliferation, migration, and recruitment. 12, 13) Together, these findings suggest that mural cell precursors may be generated by activin treatment, but that these cells could not migrate to form the vessel wall, accounting for the lack of a mural cell layer.
We also showed that red blood cells did not appear in the transplanted aggregate after a week in culture, suggesting that the transplanted tissue did not connect with the host embryo vessels. Thus no nutrition was available for the transplanted tissue, resulting in cell death. The Tie2/angiopoietin pathway regulates vascular remodelling, although the molecular mechanism underlying this effect is unclear. 14, 15) We speculate therefore that co-treatment of the aggregate-derived cells with activin and angiopoietin would induce remodelling of the endothelial cells, resulting in connection of the host and newly formed blood vessels in the transplanted aggregate.
We previously reported the weak expression of endothelial cell markers in activin-treated aggregates, and no expression of hematopoietic markers. 10) However, the finding in this study that transplanted aggregates developed into hematopoietic and endothelial cells would suggest activin-induced hemangioblasts, the common precursor of vascular endothelial and hematopoietic cells. In fact, microarray analysis revealed the induction of stem cell leukemia (SCL) mRNA, a marker of hemangioblast, in aggregates formed from cells treated with activin (UniGene no. xl.278). 16, 17) We proposed that the host embryo-derived factor acted on the transplanted aggregate to differentiate hemangioblasts into hematopoietic cells.
Finally, microarray analysis implicated vascular-related receptor genes such as X-msr and PDGFR in the activintreated aggregates. This result presumes that other novel vascular-related genes including receptors may be presented in 186 ESTs of unknown gene that were upregulated in the activin-treated aggregates. We plan to test the expression patterns of these genes in Xenopus embryos to identify novel genes in vascular development.
In conclusion, blood and vascular endothelial cells were formed in embryos by transplantation of aggregates derived from undifferentiated presumptive ectoderm cells treated with a low concentration of activin. Furthermore, we identified candidate vascular-related genes upregulated in the activin-treated aggregates. This constructive approach in vitro should facilitate our understanding of the cellular and molecular mechanisms of vascular development.
